<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677297</url>
  </required_header>
  <id_info>
    <org_study_id>DPU/R &amp; R (D)/ 98(10)/ 16</org_study_id>
    <nct_id>NCT03677297</nct_id>
  </id_info>
  <brief_title>&quot;Efficacy Of 1.2% Rosuvastatin Gel In The Management Of Infrabony Defects&quot;</brief_title>
  <official_title>Comparative Evaluation of Treatment Of Infrabony Defects With and Without 1.2% Rosuvastatin Gel: In-Vivo Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. D. Y. Patil Dental College &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. D. Y. Patil Dental College &amp; Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study aims to evaluate clinical and radiographic effectiveness of 1.2% Rosuvastatin gel in
      the treatment of Infrabony defects in chronic periodontitis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Source from where the patients will be selected:

      10 patients with chronic periodontitis having two or more infrabony defects will be selected
      from the Outpatient section of Dept. of Periodontology, Dr. D. Y. Patil Dental College and
      Hospital, Pimpri, Pune - 18.

      A detailed clinical examination, case history and written consent will be obtained from all
      the participants.

      Before surgery, each patient will be given careful instructions regarding proper oral hygiene
      measures. A full-mouth phase I therapy will be performed. A periodontal re-evaluation will be
      performed after 4 to 6 weeks of phase 1 therapy to confirm the desired sites for the study.
      The selected sites will be divided randomly by using a Sequentially numbered, opaque, sealed
      envelopes (SNOSE) randomization into control and test sites. The control site will be treated
      with Access Flap Surgery (AFS), whereas test sites will be treated with AFS and 1.2%
      Rosuvastatin gel. Suitable antibiotics and analgesics will be prescribed along with
      Chlorhexidine digluconate rinses (0.2%) twice daily for 14 days. Patients will be examined at
      4 weeks, 3 and 6 month after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone fill</measure>
    <time_frame>6 months</time_frame>
    <description>Radiographic parameter measuring distance from cemento-enamel junction to the base of the defect.
Difference in the measurement at the end of 6 months shows the amount of bone fill</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Probing depth</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in this parameter is desired at the end of 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative attachment level</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in this parameter at the end of 6 months shows gain in attachment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plaque index</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in plaque index at the end of 6 months shows improvement in gingival health</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding index</measure>
    <time_frame>6 months</time_frame>
    <description>Clinical parameters- Reduction in bleeding index at the end of 6 months shows improvement in gingival health</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Adult Periodontitis</condition>
  <arm_group>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.2% Rosuvastatin Gel. Insertion in infrabony defects once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No intervention used on control site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Test sites were treated with access flap surgery and 1.2% Rosuvastatin gel</description>
    <arm_group_label>ROSUVASTATIN</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <other_name>No intervention used on Control site</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age group between 30-50 years

          -  Probing pocket depth ≥ 5mm following initial therapy.

          -  Suitable interproximal angular infrabony defects of ≥3mm.

          -  Involved teeth should be vital and asymptomatic.

          -  Systemically healthy patients.

          -  Patients who demonstrate acceptable oral hygiene prior to access flap surgery.

          -  Patients agreed to sign informed consent and willing to return for the follow up
             visits.

        Exclusion Criteria:

          -  Systemic statin therapy

          -  Known or suspected allergy to the statin group

          -  Allergy to sulfur containing drugs

          -  History of aggressive periodontitis.

          -  Presence of gingival recession at the surgical site.

          -  Mobility of study teeth ≥ grade I.

          -  Use of tobacco in any form.

          -  Pregnant and lactating women.

          -  patients who have received any anti-inflammatory drugs and antibiotics in the previous
             six months.

          -  H/O osteoporosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sukhada D Deo, BDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. D. Y. Patil Dental College &amp; Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sukhada Deo</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>August 17, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>September 18, 2018</last_update_submitted>
  <last_update_submitted_qc>September 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr. D. Y. Patil Dental College &amp; Hospital</investigator_affiliation>
    <investigator_full_name>DR. SUKHADA DEO</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Intervention Study</keyword>
  <keyword>Rosuvastatin</keyword>
  <keyword>Periodontitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
    <mesh_term>Chronic Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

